THERAPY DOSSIER · th-d193a93b67d3

7,8-diacetoxy-4-methylthiocoumarin (DAMTC)

Drug · 7,8-diacetoxy-4-methylthiocoumarin (DAMTC), a synthetic coumarin.

Evidence & regulatory context

Mechanism: 7,8-diacetoxy-4-methylthiocoumarin (DAMTC), a synthetic coumarin.
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31575959 ↗2019Reported benefit

Mitigation of radiation-induced gastro-intestinal injury by the polyphenolic acetate 7, 8-diacetoxy-4-methylthiocoumarin in mice.

MouseRadiationC57BL/6femaleIntraperitoneal5 microgram/kg in 100 microlitre24 h after total body irradiation

Model: Sub-lethal total body gamma irradiation at 7.6 Gy from a cobalt-60 teletherapy unit at 1 Gy/min, causing radiation-induced intestinal injury

DAMTC preserved crypt and villus architecture and restored xylose absorption through day 21, markedly reduced crypt and stromal apoptosis, lowered DNA damage markers and lipid peroxidation, and increased proliferation and antioxidant enzyme levels.

Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…